[Cluster headache and chronic paroxysmal hemicrania: current therapy].
In acute attacks of cluster headache (CH), the mainstays of treatment are inhalation of pure oxygen (due to lack of any side effects), ergotamine aerosol, and intranasal application of local anaesthetics. The following treatments have hitherto been recommended for the prevention of attacks: young patient with first manifestation-methysergide; middle aged patient with episodic or chronic CH-steroids; older patient with history of resistance to therapy-lithium. These guidelines have been superceded as a result of the demonstration of the efficacy of several other drugs which have reduced side effects. This increased variety of treatments also reduces the importance of clinical differentiation between episodic and chronic cluster headache. Today, the drugs of first choice for treatment of episodic cluster headache are steroids or calcium channel blockers like verapamil, replacing methysergide which is now drug of second choice. In chronic CH, verapamil and lithium are normally prescribed, steroids-possibly in combination with one of the other drugs-are regarded as drugs of second choice. Another possibility, used with increasing frequency, is valproate acid, and the experimental drug budipine may be a further alternative in therapy resistant patients. There is no convincing role for invasive surgical procedures, particularly in the light of the increased number of effective drugs. The treatment of choice for chronic paroxysmal hemicrania is indometacin, although individual patients may respond to salicylates, naproxene, prednisone and ergotamine.
Brandt
T
T
Neurologische Klinik, Klinikum Grosshadern, Ludwig-Maximilians-Universität München.
Paulus
W
W
Pöllmann
W
W
D003027:Cluster Headache / Q000188:drug therapy* / Q000209:etiology; D003131:Combined Modality Therapy; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000209:etiology
Clusterkopfschmerz und chronisch paroxysmale Hemikranie: aktuelle Therapie.